Abeona Therapeutics is a clinical-stage biopharmaceutical organization that develops innovative gene and cell therapies to treat life-threatening, rare genetic illnesses. The group has an autologous, gene-corrected cell therapy in the Phase III clinical trial phase for recessive dystrophic epidermolysis bullosa. It is also focused on new treatments like AAV-based gene therapies for genetic eye disorders, cystic fibrosis, and Sanfilippo syndrome type A.